0001144204-18-034065.txt : 20180613 0001144204-18-034065.hdr.sgml : 20180613 20180613163226 ACCESSION NUMBER: 0001144204-18-034065 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180607 FILED AS OF DATE: 20180613 DATE AS OF CHANGE: 20180613 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Wirostko Barbara CENTRAL INDEX KEY: 0001669087 FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-36672 FILM NUMBER: 18897055 MAIL ADDRESS: STREET 1: C/O EYEGATE PHARMACEUTICALS, INC. STREET 2: 271 WAVERLY OAKS ROAD, SUITE 108 CITY: WALTHAM STATE: MA ZIP: 02452 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: EYEGATE PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001372514 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 271 WAVERLEY OAKS ROAD STREET 2: SUITE 108 CITY: WALTHAM STATE: MA ZIP: 02452 BUSINESS PHONE: 781-788-9043 MAIL ADDRESS: STREET 1: 271 WAVERLEY OAKS ROAD STREET 2: SUITE 108 CITY: WALTHAM STATE: MA ZIP: 02452 4/A 1 tv496443_4a.xml OWNERSHIP DOCUMENT X0306 4/A 2018-06-07 2018-06-11 0 0001372514 EYEGATE PHARMACEUTICALS INC EYEG 0001669087 Wirostko Barbara C/O EYEGATE PHARMACEUTICALS, INC. 271 WAVERLY OAKS ROAD, SUITE 108 WALTHAM MA 02452 0 1 0 0 Chief Medical Officer Common Stock 2018-06-07 4 A 0 2215 0.52 A 52915 I By husband Common Stock 2018-06-07 4 A 0 9600 0.52 A 249997 D Common Stock 2018-06-08 4 A 0 7000 0.54 A 59915 I By husband The Form 4 previously filed on June 11, 2018 inadvertently misclassified the 2,215 shares purchased on June 7, 2018 and 7,000 shares purchased on June 8, 2018 as being beneficially owned directly by the reporting person instead of indirectly, and inadvertently omitted the purchase of 9,600 shares by the reporting person on June 7, 2018, which are beneficially owned directly. This amendment corrects that error to add the omitted transaction from June 7, 2018 and to reflect the correct number of shares beneficially owned by the reporting person, both directly and indirectly, after the reported transaction. /s/ Robert A. Petitt, attorney-in-fact 2018-06-13